John Alisland

AMENDMENTS TO THE CLAIMS

Claims 1-14 (canceled).

Claim 15 (currently amended) A method of determining the risk of developing diagnosing a Wnt antagonist-associated lytic bone disease characterized by bone loss in a test an individual, comprising said method comprises the step of:

examining the expression level of the human homologue of Dickkopf-1 (DKK-1) protein in said test individual, wherein <u>an</u> increased expression of said protein compared to that in <u>a</u> normal individual indicates that said test individual has the <u>risk-of-developing Wnt antagonist-associated lytic</u> bone disease.

Claim 16-17 (canceled).

Claim 18 (previously presented) The method of claim 15, wherein said expression level is determined by enzyme-linked immunosorbent assays.

Claim 19 (currently amended) The method of claim 15, wherein said test-individual has multiple myeloma.

Claims 20-38 (canceled).